Trending...
- Five Aster Awards! Fusion Marketing Group Brings Home Big Wins in 2025!
- Pride Takes Center Stage in Ghostlight Ensemble Theatre Co's 9th Season
- 14th CryptoSuper500 Report Releases: Bitcoin's Evolution into a Global Supercomputer
CHICAGO, June 23, 2025 ~ New studies have revealed promising results for two medications, orfoglipron and MariTide, in the treatment of type 2 diabetes and obesity. The findings from the ACHIEVE-1 Trial and the MariTide Phase 2 Trial were simultaneously published in the New England Journal of Medicine (NEJM) and presented at the American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago.
According to recent statistics, more than 2 in 5 adults in the US are obese or severely obese, while an estimated 90 to 95% of over 38 million Americans with diabetes have type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists are a well-established treatment option for both conditions. However, there is a growing need for additional options that cater to patient preferences and provide tailored care, such as oral forms or injectables with less frequent dosing.
The MariTide Phase 2 Trial, which enrolled 592 adults, demonstrated weight loss and A1C reduction in both groups with and without type 2 diabetes. This trial evaluated MariTide, a novel long-acting GLP-1 receptor agonist and GIP receptor antagonist. Participants were assigned to different monthly fixed dose regimens or an every-8-week dose regimen. The results showed an average weight loss of up to approximately 20% in participants with obesity alone and a weight loss and A1C reduction of up to approximately 17% and 2.2%, respectively, in those with obesity and type two diabetes. Additionally, there were improvements in other cardiometabolic measures such as blood pressure and lipid levels. These positive outcomes suggest that MariTide has the potential to be a once-monthly treatment option for both conditions.
More on illi News
Dr. Ania M. Jastreboff, professor at Yale School of Medicine (Endocrinology) and director of the Y-Weight Yale Obesity Research Center, expressed her excitement about the potential of MariTide as a once-monthly treatment option for people with obesity. She stated, "Once-monthly treatment options for type 2 diabetes have long been sought after, yet elusive. MariTide has the potential to be a once-monthly treatment option for people with obesity, with and without type 2 diabetes, resulting in substantial weight reduction and robust improvements in glycemia."
The study also revealed that more than 90% of eligible participants have enrolled for an additional 52 weeks of the study (Part 2). This second part will evaluate the impact of MariTide on sustained weight loss with lower doses, less frequent dosing, or discontinuation and is expected to conclude later this year.
In another breakthrough study, the ACHIEVE-1 Trial demonstrated the safety and effectiveness of orfoglipron, the first oral small molecule non-peptide GLP-1 RA to successfully complete a Phase 3 trial. The trial enrolled 559 patients with type 2 diabetes who were not taking any glucose-lowering medications and had inadequate glycemic control across multiple countries. The results showed that orfoglipron significantly lowered A1C levels by an average rate of 1.3% to 1.6% across doses from a baseline of 8.0%. Additionally, participants experienced an average weight loss of 7.9% (roughly 16lbs) at the highest dose, with indications of further potential weight loss as they did not reach a plateau at the end of the study.
More on illi News
One significant advantage of orfoglipron is that it can be taken as a once-daily pill without any food or water restrictions. This contributed to approximately 73% of participants in the treatment regimen achieving their A1C target, with a potential increase up to 76%.
These groundbreaking studies provide hope for individuals with type 2 diabetes and obesity, as they offer new treatment options that can potentially lead to significant weight loss and improved glycemic control. The results of these trials have been published in prestigious medical journals and presented at a major scientific conference, highlighting their significance in the field of diabetes and obesity research.
According to recent statistics, more than 2 in 5 adults in the US are obese or severely obese, while an estimated 90 to 95% of over 38 million Americans with diabetes have type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists are a well-established treatment option for both conditions. However, there is a growing need for additional options that cater to patient preferences and provide tailored care, such as oral forms or injectables with less frequent dosing.
The MariTide Phase 2 Trial, which enrolled 592 adults, demonstrated weight loss and A1C reduction in both groups with and without type 2 diabetes. This trial evaluated MariTide, a novel long-acting GLP-1 receptor agonist and GIP receptor antagonist. Participants were assigned to different monthly fixed dose regimens or an every-8-week dose regimen. The results showed an average weight loss of up to approximately 20% in participants with obesity alone and a weight loss and A1C reduction of up to approximately 17% and 2.2%, respectively, in those with obesity and type two diabetes. Additionally, there were improvements in other cardiometabolic measures such as blood pressure and lipid levels. These positive outcomes suggest that MariTide has the potential to be a once-monthly treatment option for both conditions.
More on illi News
- Carlonoscopen Launches Base-Zero Number System — A New Mathematical Language for Tomorrow's Tech
- New Study Reveals Nearly Half Of TikTok Shop Stores Generate Zero Sales Despite Platform's $100 Million Black Friday Success
- Speranza Dental Implant Centers Opens Their First Location
- Erin Borst Crowned Winner of eATLAS' 2025 Flavors of Chicago Scavenger Hunt
- Chicago: Mayor Brandon Johnson Announces Juneteenth Task Force Members
Dr. Ania M. Jastreboff, professor at Yale School of Medicine (Endocrinology) and director of the Y-Weight Yale Obesity Research Center, expressed her excitement about the potential of MariTide as a once-monthly treatment option for people with obesity. She stated, "Once-monthly treatment options for type 2 diabetes have long been sought after, yet elusive. MariTide has the potential to be a once-monthly treatment option for people with obesity, with and without type 2 diabetes, resulting in substantial weight reduction and robust improvements in glycemia."
The study also revealed that more than 90% of eligible participants have enrolled for an additional 52 weeks of the study (Part 2). This second part will evaluate the impact of MariTide on sustained weight loss with lower doses, less frequent dosing, or discontinuation and is expected to conclude later this year.
In another breakthrough study, the ACHIEVE-1 Trial demonstrated the safety and effectiveness of orfoglipron, the first oral small molecule non-peptide GLP-1 RA to successfully complete a Phase 3 trial. The trial enrolled 559 patients with type 2 diabetes who were not taking any glucose-lowering medications and had inadequate glycemic control across multiple countries. The results showed that orfoglipron significantly lowered A1C levels by an average rate of 1.3% to 1.6% across doses from a baseline of 8.0%. Additionally, participants experienced an average weight loss of 7.9% (roughly 16lbs) at the highest dose, with indications of further potential weight loss as they did not reach a plateau at the end of the study.
More on illi News
- Chicago Is Joined by Major Cities in Challenging the Department of Homeland Security for Freezing Critical Counterterrorism Funds
- Naperville Police Participate in Independence Day Traffic Safety Campaign
- WWSG Announces Exclusive Speaking Partnership with Former Australian Prime Minister Tony Abbott
- Aidaptive and BizCor Expand Inhabit Partnership with Native Enterprise-Grade Search for Streamline Customers
- Pikmykid Partners with Vivi to Enhance School Emergency Communication and Safety
One significant advantage of orfoglipron is that it can be taken as a once-daily pill without any food or water restrictions. This contributed to approximately 73% of participants in the treatment regimen achieving their A1C target, with a potential increase up to 76%.
These groundbreaking studies provide hope for individuals with type 2 diabetes and obesity, as they offer new treatment options that can potentially lead to significant weight loss and improved glycemic control. The results of these trials have been published in prestigious medical journals and presented at a major scientific conference, highlighting their significance in the field of diabetes and obesity research.
Filed Under: Business
0 Comments
Latest on illi News
- Sploot Veterinary Care Brings Modern Pet Care to Forest Park with New Clinic Opening June 23, 2025
- Anti-war groups protest vs US-NATO actions in Gaza, Iran, the Global South
- Dr. Jacqueline West Honored as Best Dentist in JAX by Folio Weekly
- Naperville Police Investigate Fatal Traffic Crash at Chicago Avenue and Naper Boulevard
- The American Diabetes Association Demonstrates Its Commitment to Curbing the Obesity Epidemic with Obesity Standards of Care
- Exciting News: Pivotal Health Solutions Acquires Revolutionary Portable Parallel Bars
- Miboxer Achieved New Goal in GILE 2025
- Jeopardy!'s Ken Jennings Headlines National Mensa Event
- Mensa Foundation Prize Awarded to Neuroscientist-Pianist
- New book, "High-Tech Heroes," redefines billionaire as someone who improves a billion lives
- Durex Products Wire Cloth Screen Media: Engineered for Maximum Performance and Durability
- OPRAH.COM Featured Award-Winning Novel AS FAR AS YOU GO BEFORE YOU HAVE TO COME BACK now Available as Audiobook
- How Kallie Boxell Helps Texas Companies Solve the Talent Equation
- Naperville: Structure Fire in the 1500 Block of West Jefferson Avenue
- KeysCaribbean Vacation Home Rentals Offers Last-Minute Booking Discount of 15 Percent
- purelyIV Blog Named One of the Top 45 IV Therapy Blogs by Feedspot
- purelyIV Launches Mobile Iron Infusion Therapy for Patients with Iron Deficiency Anemia
- Zhang Financial Sponsors Distinguished Juror Li-Wei Qin and Historic Instrument Selection for Stulberg's 50th Anniversary
- Smile Makers Dental Care Introduces FP1: East Bay's First Robotic-Assisted Full-Arch Implant Solution for Natural, Fixed Smiles
- DCAS College opens new Representative Office in Malaysian Capital Kuala Lumpur